 SALT LAKE CITY, Feb. 02, 2021 GLOBE NEWSWIRE -- To help more patients with rheumatoid arthritis RA, Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, today launched the new Vectra Cardiovascular Risk assessment that can predict the risk for cardiovascular CV events in patients with RA. This new test result incorporates information on RA inflammation assessed by Vectra Score and three additional biomarkers, combined with traditional risk factors. Vectra is an advanced blood test that objectively measures inflammation caused by RA. 